Ionis Pharmaceuticals announced that its Phase-3 CARDIO-TTRansform trial did not meet its primary endpoint, causing the company's shares to fall over 20%. The trial aimed to reduce cardiovascular death and recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy but failed to deliver expected results. The legal firm Levi & Korsinsky is investigating whether Ionis made misleading statements about the trial's progress and expected outcomes. Investors who suffered losses are encouraged to contact the firm as a potential securities law violation case develops.
The inaugural Juneteenth Exchange summit in Rancho Cordova gathered over 150 leaders from business, technology, and investment sectors to discuss innovation, economic opportunity, and inclusive leadership. The event highlighted the city's growing app...
Canon U.S.A., Inc. has been awarded the 2026-2028 Most Energy Efficient Toner-Based A3 and A4 Brand Awards by Keypoint Intelligence, recognizing its commitment to energy-conscious printer design. The awards are based on a new testing methodology eval...
Hyperliquid Policy Center and Phantom Technologies jointly asked the Commodity Futures Trading Commission (CFTC) to clarify that developers who write onchain protocol software should not be required to register as regulated entities. They argue that ...
Solana's price remains stable near $78 despite bearish market sentiment, supported by a surge in tokenized real-world assets (RWA) on its blockchain, which reached a record $3.62 billion. Institutional interest is growing with new derivatives product...
ApeCoin (APE) broke out of a tight trading range, rising 15% to $0.168 driven by increased buying demand and a 218% surge in trading volume. Both spot and derivatives markets showed strong participation, with buyers retaking control and pushing open ...
